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RESEARCH ARTICLE

Akt3 is responsible for the survival and proliferation of embryonic
stem cells

ABSTRACT
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt)
pathway plays an important role in regulating cell proliferation,
metabolism, and survival. However, the distinct roles of Akt
isoforms (Akt1, Akt2, and Akt3) in pluripotent stem cell
maintenance are not fully defined. Using mouse embryonic stem
cells (ESCs), we show that direct inhibition of Akt activity leads to ESC
apoptosis. The Akt3, but not Akt1 or Akt2, activity specifically
regulates this effect. Inhibiting Akt3 also leads to a cell cycle arrest at
G1 phase. These regulatory roles of Akt3 are dependent on its kinase
activity. Blocking the expression of Akt1 plus Akt2 in ESCs does not
affect cell survival or proliferation, although blocking Akt1 aggravates
the apoptotic effect induced by depletion of Akt3. We further show that
blocking Akt3 in ESCs results in significant nuclear accumulation of
p53, as well as the activation of its downstream targets, such as
Mdm2, p21, and Fas. Inhibiting p53 and its downstream targets
partially rescued the effects caused by Akt3-depletion. Our results
revealed an Akt3 isoform-specific mechanism for ESC survival and
proliferation involving the control of p53 activity.
KEY WORDS: Akt3, Embryonic stem cells, Cell survival, Cell cycle,
p53

INTRODUCTION

The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt)
pathway plays a central role in mediating extracellular stimuli that
controls diverse functions including cell proliferation, growth, survival,
and metabolism (Manning and Cantley, 2007; Vanhaesebroeck and
Alessi, 2000). Activated by receptor tyrosine kinases, PI3K converts
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol3,4,5-trisphosphate (PIP3), which recruits the Akt serine-threonine
kinase to the plasma membrane, where Akt is phosphorylated and
activated by mammalian target of rapamycin complex 2 (mTORC2)
and phosphoinositide-dependent kinase 1 (PDK1) at Ser473 and
Thr308, respectively (Alessi et al., 1997; Sarbassov et al., 2005).
Activated Akt then phosphorylates its downstream targets to regulate
various cellular events. This process can be reverted by phosphatase
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and tensin homolog (Pten), which dephosphorylates PIP3 to PIP2,
thereby inhibiting Akt activation (Maehama and Dixon, 1998; Paling
et al., 2004; Stambolic et al., 1998).
There are three Akt isoforms encoded by different genes, namely
Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ, which all contain
conserved peptide sequences between mice and humans
(Bellacosa et al., 1991; Brodbeck et al., 1999; Cheng et al.,
1992). These three isoforms share a similar N-terminal Pleckstrinhomolog domain, a central serine-threonine kinase domain, and a Cterm hydrophobic motif-containing regulatory region characteristic
of the protein kinase-A, -G, and -C families (Hanada et al., 2004;
Manning and Cantley, 2007; Yang et al., 2004). In mice, both Akt1
and Akt2 mRNAs are expressed ubiquitously in various tissues,
with the highest Akt2 expression in insulin-responsive tissues
including fat, skeletal muscle and liver (Altomare et al., 1998; Cho
et al., 2001a). The expression of Akt3, however, is restricted in
selective organs including the brain, testis, lung, mammary gland,
and fat (Yang et al., 2003). These expression patterns also correlate
with observations from knockout studies, which revealed a general
association of Akt1 with organismal growth and cell survival (Chen
et al., 2001; Cho et al., 2001b); Akt2 with glucose metabolism (Cho
et al., 2001a; Garofalo et al., 2003); and Akt3 with brain
development (Tschopp et al., 2005). However, the specific roles
of each Akt isoform in different cell types are largely undefined
(Chin and Toker, 2011).
Embryonic stem cells (ESCs) hold enormous promise in
regenerative medicine because of their pluripotency and capacity
for self-renewal. Although it has been reported that in murine ESCs,
inhibition of PI3K suppresses and knockout of Pten increases Akt
activity and cell proliferation (Jirmanova et al., 2002; Lianguzova
et al., 2007; Sun et al., 1999), the functional correlation between
direct inhibition of specific Akt isoforms and ESC growth is not
understood. At the same time, ESCs share similar properties with
cancer stem cells, such as high cell proliferation rates and the
presence of many ESC-specific genes and regulatory pathways in
various types of tumors (Ben-Porath et al., 2008; Kim and Orkin,
2011; Wong et al., 2008). Isoform-specific Akt abnormalities have
been reported in many cancer cells, such as the overexpression of
Akt1 in thyroid and non-small cell lung cancers (Lee et al., 2011;
Saji et al., 2011), Akt2 and Akt3 in malignant glioma (Mure et al.,
2010; Turner et al., 2015; Zhang et al., 2009), and Akt3 in
melanoma, ovarian, and breast cancer (Chin et al., 2014; Grabinski
et al., 2014; Madhunapantula et al., 2011; Stahl et al., 2004; Turner
et al., 2015). The underlying mechanism of these Akt isoform
dysregulations, however, is largely unclear. Therefore,
understanding Akt isoform-specific regulation in ESCs may
provide important insight not only for stem cell therapy, but also
for cancer target identification and treatment.
In this study, we investigated the specific roles of the Akt
isoforms in mouse ESCs. We report here an Akt3-dependent ESC
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survival and proliferation mechanism, which involves suppressing
the p53 activity.
RESULTS
Blocking Akt activity results in ESC apoptosis

We used MK2206 (MK), an Akt-specific allosteric inhibitor (Hirai
et al., 2010), to determine the effect of a direct Akt inhibition on the
growth of ESCs. Mouse R1 ESCs were grown in 2i/leukemia
inhibitory factor (LIF) medium (Silva et al., 2008; Ying et al., 2008),
with dual inhibition to the extracellular-signal-regulated kinases 1/2
and the glycogen synthase kinase 3-beta, to study Akt signaling
with minimum extracellular stimuli. Within 24 h of applying MK
(0–10 µM) to 2i/LIF medium, we observed a dose-dependent
inhibition to ESC colony growth, and obviously detached, dead
cells in the medium (Fig. 1A). Annexin V apoptosis assay by flow
cytometer revealed a significant increase in cell apoptosis and
decrease in live cell population at 5 and 10 µM MK levels (Fig. 1B).
We then asked if inhibiting Akt expression by short hairpin RNA
(shRNA) could produce the same effect. We previously reported
Akt isoform-specific knockdown in mouse embryonic fibroblasts
(MEFs) using lentiviral shRNA constructs: shAkt1, shAkt2, and
shAkt3 (for maximum Akt3 knockdown, shAkt3 consists of two
constructs: shAkt3a and shAkt3b targeting different coding regions
of Akt3) (Tang et al., 2014). We first tested the effectiveness of these
constructs in ESCs. Western blot analysis revealed barely detectable
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levels of Akt isoform 1, 2, or 3, three days after the lentiviral shAkt1,
shAkt2, or shAkt3 infection, respectively (Fig. 1C). To block all
Akt isoform expression, we seeded R1-ESCs at a clonogenic density
at day 0, together with the lentiviral shAkt1 plus shAkt2 and shAkt3
(shAkt1/2/3). Similar to the MK treatment, Akt knockdown led to
obvious cell detachment, with much smaller colonies compared to
the control (shCtl) at day 4 (Fig. 1D). Annexin V analysis again
confirmed significantly increased cell apoptosis and decreased live
cell population (Fig. 1E). Thus, results from MK and shRNAs
confirmed an essential role of Akt activity in ESC survival.
Akt3, but not Akt1 or Akt2, is responsible for ESC survival

We then examined which Akt isoform functions specifically to
improve the survival of ESCs. Using lentiviral shRNAs, we either
individually blocked each isoform or Akt isoform 1 plus 2 (shAkt1/
2). At day 3 of viral infection, we found that blocking Akt3, but not
Akt1, Akt2, or Akt1 plus 2, resulted in an inhibition of colony
growth and obvious floating, dead cells (Fig. 2A). Annexin V
analysis further confirmed that a specific knockdown of Akt3, but
not Akt1 and 2, led to significant apoptosis (Fig. 2B). As shAkt3
constructs (containing shAkt3a and -3b) target only the coding
region of Akt3, we developed another lentiviral construct – shAkt3d
to specifically target its 3′-untranslated region, and observed a
similar apoptotic effect upon applying it to ESCs (Fig. 2C). To
further confirm the specificity of our shRNA experiment, we

Fig. 1. Blocking Akt activity leads to ESC apoptosis. (A) R1-ESCs grown in 2i/LIF medium plus DMSO control or 1–10 µM of MK for 24 h. Scale bar: 250 µm.
(B) R1 ESCs treated as described in A were incubated with Annexin V-FITC (Annex) and Propidium Iodide (PI) for 30 min and analyzed by flow cytometry.
Percentages of late apoptotic/necrotic (Annex+/PI+), early apoptotic (Annex+), and live cells (unstained) are shown (data shown are mean±s.d., **P<0.01, n=3).
(C) Western blot of total protein extracts from ESCs 3 days after lentiviral control (shCtl), shAkt1, shAkt2, and shAkt3 transduction, respectively. Proteins were
blotted with the respective Akt antibodies with GAPDH used as a loading control. (D) ESCs expressing lentiviral shCtl or a combination of shAkt1, shAkt2, and
shAkt3 (shAkt1/2/3) for 2 and 4 days, respectively, in 2i/LIF medium. Scale bar: 250 µm. (E) ESCs treated as described in D were incubated with Annex and PI for
30 min and analyzed by flow cytometry. Percentage of early, late apoptotic and live cells were determined as described in B (data shown are mean±s.d., *P<0.05,
**P<0.01, n=2).
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pre-expressed a myristoylated, constitutively active Akt3 (CAAkt3) in ESCs (CA-Akt3/R1), and inhibited endogenous Akt using
lentiviral shAkt3d. Compared to the vector control, CA-Akt3 led to
an obvious recovery to the number of attached ESCs (Fig. 2D). This
was correlated with partially but significantly rescued cell apoptosis
caused by Akt3-knockdown (Fig. 2E). Thus, among the three Akt
isoforms, the expression of Akt3 is specifically responsible for
regulating the survival of ESCs.
852

Akt3 specifically regulates G1/S cell cycle transition in ESCs

Akt1 and Akt2 activities have been reported to play roles for
G1/S and G2/M transition in cancer and other somatic cells (Hers
et al., 2011; Toker and Marmiroli, 2014). To confirm a direct Akt
activity on ESC cell cycle progression, we first blocked all three
Akt isoforms with the lentiviral shAkt1/2/3, and specifically
monitored the attached cells at day 3 using propidium iodine (PI)
and flow cytometry (Pozarowski and Darzynkiewicz, 2004). A
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Fig. 2. Blocking Akt3 activity specifically leads to ESC apoptosis. (A) R1-ESCs expressing lentiviral shCtl, shAkt1, shAkt2, shAkt1 and 2 (shAkt1/2), or
shAkt3 for 2 and 3 days and cultured in 2i/LIF medium. Scale bar: 250 µm. (B) ESCs treated as described in A for 3 days were incubated with Annex and PI
for 30 min and analyzed by flow cytometry. Percentages of early and later apoptotic cells and live cells are shown (data shown are mean±s.d., **P<0.01, n=3).
(C) R1-ESCs expressing lentiviral shCtl, shAkt3a, or shAkt3d construct for 3 days were incubated with Annex and PI for 30 min and analyzed by flow cytometry
(data shown are mean±s.d., *P<0.05, n=2). (D) R1-ESCs overexpression CA-Akt3 (CA-Akt3/R1) or a vector control (Ctl/R1) were treated with lentiviral shCtl or
shAkt3d on day 0 and grown for 4 days with cell numbers counted (data shown are mean±s.d., **P<0.01, n=2). (E) ESCs treated as in D and grown for 3 days were
subjected to Annexin V apoptosis assay. Percentages of early and later apoptotic as well as live cells are shown (data shown are mean±s.d., **P<0.01, n=2).

significant increase was observed for cell population at G1 (34%
versus ∼20%) by Akt-knockdown (Fig. 3A). This confirms a
requirement of Akt activity for the G1/S transition in ESCs.
Subsequently, we asked which Akt-isoform deletion might be
responsible for the observed G1-arrest. We individually blocked
these Akt isoforms using lentiviral shRNAs and found that
blocking Akt1, Akt2, or Akt1 plus 2 had no significant impact
on the cell cycle progression of ESCs (Fig. 3B). However,
blocking Akt3 alone by various lentiviral constructs resulted in
significant G1-arrest (Fig. 3C,D). We then wondered whether
enhanced activation of Akt3 would promote the cell cycle
progression. Indeed, CA-Akt3 overexpressing ESCs exhibited
decreased G1 cell population, although there was no significant
change to cell viability, compared to the control cells (Fig. 3E
and Fig. 2E). Thus, these data demonstrated that the Akt3
isoform specifically promotes G1/S transition in ESCs, in
addition to its role in cell survival.
We also cultured ESCs in 20% FBS supplemented with LIF, and
examined the effect of individual Akt isoform knockdown to the
growth of colonies. Again we observed obvious cell death and
reduced colony sizes that are specific to Akt3 depletion similarly as
in 2i/LIF medium (Fig. S1). Thus it is clear that the Akt3-dependent
ESC survival and proliferation is not restricted to the 2i/LIF medium
used in this study.
Akt3 regulates ESC survival and proliferation through its
kinase activity

Inhibiting PI3K, the upstream Akt kinase activator, results in cell
cycle arrest and apoptosis in ESCs (Jirmanova et al., 2002;
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Lianguzova et al., 2007). However, a kinase-independent function
of Akt was also reported for cell survival in cancer cells (Vivanco
et al., 2014). We wondered whether the Akt3-mediated ESC
survival and proliferation is dependent on Akt kinase activity. To
this end, we mutated the ATP binding site of Akt3 with the lysine
177 changed to methionine (KD-Akt3) at a position comparable to
the reported Akt1 kinase-dead mutant K179M (Bellacosa et al.,
1993; Franke et al., 1995). ESCs stably expressing KD-Akt3 did not
show reduced cell growth compared to the control (Fig. S2A). We
suspected that the endogenous Akt kinase activity in ESCs might
compensate for the KD-Akt3. We then used the PI3K inhibitor
LY294002 (LY) to minimize the activation of the endogenous Akt
kinase in ESCs. 40 μM LY treatment significantly inhibited the
growth of R1 ESCs (Fig. 4A), induced cell apoptosis and G1-arrest
similar to that reported previously (Jirmanova et al., 2002;
Lianguzova et al., 2007) and similar to that of Akt3-knockdown
here (Fig. S2B,C; Fig. 2C and Fig. 3D). We then examined the
growth of ESCs under the LY treatment and overexpressing CAAkt3 or KD-Akt3. A partial CA-Akt activity would be expected
here, as reduced PIP3 production caused by LY inhibition of PI3K
will impair the ability of PDK1 to phosphorylate Akt (Primo et al.,
2007). Despite the LY treatment, ESCs overexpressing CA-Akt3
showed significant improvement on cell growth, while the KD-Akt3
expressing ESCs did not improve on total cell number compared to
the vector control (Fig. 4B), even though both expressed similar
levels of retroviral Akt3 (Fig. 4C). Annexin V and cell cycle assay
further revealed that CA-Akt3 expression partially but significantly
rescued the apoptosis and G1-arrest caused by LY treatment,
whereas the expression of KD-Akt did not show any rescue effect

Fig. 3. Akt3 is responsible for G1/S transition in ESCs. (A) ESCs expressing lentiviral shCtl or shAkt1/2/3 for 3 days were incubated with PI and RNase for
30 min and subjected to cell cycle analysis by flow cytometry. The percentages of cell in G1, S, and G2 phases are shown on the right (data shown are mean±s.d.,
*P<0.05, **P<0.01, n=2). (B) Cell cycle analysis of R1-ESCs treated with shCtl, shAkt1, shAkt2, or shAkt1 plus 2 (shAkt1/2) for 3 days and cultured in 2i/LIF
medium. The percentages of cell in G1, S, and G2 phases are shown on the right (data shown are mean±s.d., n=2). (C) Cell cycle analysis of R1-ESCs treated
with shCtl or shAkt3 for 3 days and cultured in 2i/LIF medium. The percentages of cells in G1, S, and G2 phases are shown on the right (data shown are mean±s.d.,
**P<0.01, n=2). (D) Cell cycle analysis of R1-ESCs treated with shCtl, shAkt3a, or shAkt3d for 3 days and cultured in 2i/LIF medium. The percentages of cells in
G1, S, and G2 phases are shown on the right (data shown are mean±s.d., **P<0.01, n=2). (E) Cell cycle analysis of R1-ESCs overexpressing CA-Akt3 (CA-Akt3/
R1) or a vector control (Ctl/R1). The percentages of cells in G1, S, and G2 phases are shown (data shown are mean±s.d., *P<0.05, n=2).
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Fig. 4. Akt3 mediates ESC survival and proliferation through its kinase activity. (A) R1-ESCs were seeded in 12-well plates and grown in 2i/LIF medium on
day 0, treated with 0 μM, 20 μM or 40 μM LY294002 (LY0, LY20, or LY40) on day 2 and cell number counted 24 h later (day 3) (data shown are mean±s.d.,
*P<0.05, n=2). (B) R1-ESCs expressing pMCs vector control (Ctl/R1), CA-Akt3 (CA-Akt3/R1), or KD-Akt3 (KD-Akt3/R1) were seeded in 12-well-plates and grown
in 2i/LIF medium on day 0, cultured with 40 μM LY294002 (LY) on day 2 and cell number counted 24 h later (day 3) (data shown are mean±s.d., **P<0.01, n=2).
(C) qRT-PCR analysis of RNAs from Ctl/R1, CA-Akt3/R1, and KD-Akt3/R1 ESCs with primers amplifying both ectopic and endogenous Akt3 expression. All
values were normalized to GAPDH and relative to the expression of Ctl/R1 ESCs (data shown are mean±s.d.). (D) R1-ESCs expressing pMCs vector control (Ctl/
R1), and ESCs treated as described in (B) with LY for 3 days were incubated with Annex and PI on day 3 for 30 min and analyzed by flow cytometry. Percentages
of live, early and later apoptotic cells are shown (data shown are mean±s.d., **P<0.01, n=2). (E) R1-ESCs expressing pMCs vector control (Ctl/R1), and ESCs
treated as described in B with LY for 3 days were incubated with PI and RNase for 30 min and subjected to cell cycle analysis. The percentages of cell in G1, S,
and G2 phases are shown (data shown are mean±s.d., **P<0.01, n=2).

(Fig. 4D,E). Therefore, we conclude that the regulatory role of Akt3
on ESC survival and proliferation is largely, if not all, dependent on
its kinase activity.
854

Akt3 regulates p53 protein expression in ESCs

We wondered which downstream pathway might be responsible for
Akt3-dependent ESC survival and G1/S transition. We examined 36
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genes whose expressions are regulated by various Akt downstream
targets (Fig. 5A). Knockdown of Akt3, but not Akt1 or 2, showed a
marked increase in the expression of p53 responsive genes related to
apoptosis and cell cycle control, such as Reprimo (Ohki et al., 2000),
Fas (Müller et al., 1998), p53 apoptosis effector related to PMP-22
(Perp) (Attardi et al., 2000), Noxa (Oda et al., 2000), and the p53
direct target and negative regulator mouse double minute 2 homolog
(Mdm2) (Barak et al., 1993; Juven et al., 1993; Perry et al., 1993)
(Fig. 5A). These data indicate that depletion of Akt3 may lead to the
activation of p53 in ESCs. We therefore asked whether the expression
of p53 would vary upon Akt3 knockdown. Western blot analysis
revealed that blocking Akt3 by different shRNAs, but not blocking
Akt1 or -2, led to increased p53 protein expression (Fig. 5B,C). This
was also accompanied by an increase in the protein level of Mdm2,
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the direct p53 target (Fig. 5C). Also, the level of p53 protein was not
affected with a dual-depletion of Akt1 and -2 (Fig. S3, left panel),
whereas an additional knockdown of Akt3 stimulated p53 (Fig. S3,
right panel). Furthermore, immunostaining of p53 protein revealed a
significant accumulation of p53 in ESC nucleus, which depends on
the depletion of Akt3, but not Akt1 or Akt2 (Fig. 5D).
Although we found that Akt3 specifically regulates p53 at the
protein level, we did not detect an increase in p53 mRNA upon
Akt3-depletion in ESCs (Fig. 5E). In addition to the increased
expression of the p53 targets mentioned above, we also found the
up-regulation of p21 (Fig. 5E), a major p53 direct target involved in
p53-dependent G1 arrest (Brugarolas et al., 1995; Deng et al.,
1995). Taken together, our data indicate that in ESCs, Akt3
specifically suppresses p53 protein activity post-transcriptionally.

Fig. 5. Akt3 knockdown results in increased p53 activity post-transcriptionally. (A) qRT-PCR analysis of RNAs from R1-ESCs treated with lentiviral shCtl,
shAkt1, shAkt2, or shAkt3 for 3 days and cultured in 2i/LIF medium. All values were normalized to GAPDH and relative to the expression of shCtl ESCs.
(B) Western blot of whole protein extracts from ESCs treated with lentiviral shCtl or shAkt3d and grown for 3 days. The specific proteins probed were p53 and Akt3.
Protein levels of p53 were quantified using the BioRad Gel Doc Densitometry software. All values were normalized to GAPDH and relative to the expression of
shCtl ESCs (data shown are mean±s.d., *P<0.05, n=2). (C) Western blot of whole protein extracts from ESCs treated with lentiviral shCtl, shAkt1, shAkt2, or
shAkt3 for 3 days and cultured in 2i/LIF medium. The specific proteins probed were phospho (P) Mdm2, Mdm2, p53, pGSK3β, pAkt, and pan-Akt. Protein levels of
pMdm2, Mdm2, p53, pAkt, pan-Akt, and pGSK3β were quantified using the ImageJ software. All values were normalized to GAPDH and relative to the expression
of shCtl ESCs (data shown are mean±s.d., *P<0.05, **P<0.01, n=2). (D) Immunostaining of ESCs treated as described in (C). Cells were stained with antibodies
for p53 and the stem cell surface marker SSEA-1. Cell nuclei were counterstained with DAPI. Scale bar: 10 µm. Fluorescence signals under each condition
were quantified using the ImageJ software, the mean ratios of p53 and DAPI relative to the control ESCs were shown (data shown are mean±s.d., **P<0.01, n=5).
(E) qRT-PCR analysis on RNAs from R1-ESCs treated with either shCtl, shAkt1, shAkt2, or shAkt3d lentiviruses for 3 days and cultured in 2i/LIF medium. All
values were normalized to GAPDH and relative to ESCs treated with shCtl (data shown are mean±s.d., *P<0.05, n=3).
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Akt1 deletion aggravates the apoptosis induced by Akt3
knockdown in ESCs

Interestingly, although blocking Akt1 plus -2 in ESCs by shAkt1/2
did not affect ESC survival and proliferation (Fig. 2B and Fig. 3B),
we had noticed that ESCs with Akt3 depletion increased the
expression of the other two Akt isoforms, especially Akt1 at both
protein (Fig. 1C) and mRNA levels (Fig. 5E). This is correlated with
an increase of phospho-pan-Akt ( pAktS473), and the increased
levels of phospho-GSK3β ( pGSK3βS9) and phospho-Mdm2
( pMdm2S166), a direct indication of increased Akt kinase activity
(Alarcon-Vargas and Ronai, 2002; Cross et al., 1995; Ogawara
et al., 2002) (Fig. 5C).
As we had observed that not all ESC population underwent
apoptosis upon Akt3-knockdown (as indicated by the percentage of
live cells) through our experiments, the increased Akt1 expression
in Akt3-depleted ESCs may thus reflect a cell response to maintain
survivability. We therefore examined whether a concurrent Akt1
inhibition will produce more prominent ESC apoptosis than
inhibiting Akt3 alone. Indeed a combined Akt1/3 knockdown
resulted in greater apoptosis rate in ESCs compared to targeting
Akt3-only (Fig. 6A), even though depleting Akt1 alone had no
apoptotic effect (Fig. 2B). Consequently, we observed a greater
reduction to the number of attached, viable ESCs by combined
Akt1/3 knockdown than by depleting Akt3 only at 3 and 6 days after
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lentiviral shRNA infection (Fig. 6B). These data are in agreement
with the previous in vivo studies showing that Akt1−/−/Akt3−/−
mice were embryonic lethal whereas Akt3−/− mice were viable
postnatally (Tschopp et al., 2005; Yang et al., 2005). However, a
combined Akt1/3 knockdown induced no additional increase in G1
arrest than the depletion of Akt3 alone in ESCs (Fig. 6C). Taken
together, our data demonstrated that blocking Akt1 expression can
exacerbate the apoptosis induced by Akt3 knockdown in ESCs, and
indicated a compensatory role for ESC survival by increased Akt1
activity in the event of Akt3-depletion.
p53 activation is a critical event for Akt3 regulated ESC
survival and proliferation

As we discovered that knockdown of Akt3 leads to increased p53
protein expression, we asked whether inhibiting p53 expression
might reverse the effects seen in Akt3 depletion. We used a
lentiviral construct against p53 (shp53) with more than 90%
knockdown efficiency in both MEFs and ESCs (Fig. S4A). R1ESCs were transduced with lentiviral shp53 (shp53/R1) or shCtl
(shCtl/R1) and pre-selected with puromycin for 3 days. These cells
(shp53/R1 and shCtl/R1) were then seeded at clonogenic density
and transduced with lentiviral shCtl or shAkt3d. We found that
compared to the shCtl/R1 cells, inhibiting p53 in ESCs (shp53/R1)
partially rescued the G1-arrest and apoptosis caused by shAkt3d

Fig. 6. Depletion of Akt1 aggravates ESC apoptosis induced by Akt3 knockdown. (A) R1-ESCs expressing lentiviral shCtl, shAkt3d, shAkt1 and -3d (shAkt1/
3) for 3 days were incubated with Annex and PI for 30 min and analyzed by flow cytometry. Percentages of early and later apoptotic cells and live cells are shown
(data shown are mean±s.d., **P<0.01, n=3). (B) R1-ESCs were transduced with lentiviral shCtl, shAkt3d, or shAkt1/3 at day 0, and cell numbers were counted at
day 2, 3, 4, 6 with Trypan blue solution under the microscope (data shown are mean±s.d., *P<0.05, **P<0.01, n=2). (C) R1-ESCs expressing lentiviral shCtl,
shAkt3d, or shAkt1/3 for 3 days were incubated with PI and RNase for 30 min and subjected to cell cycle analysis. The percentages of cell in G1, S, and G2
phases are shown (data shown are mean±s.d., **P<0.01, n=2).
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infection (Fig. 7A,B), although we also observed a near complete
rescue of apoptosis when only a mild degree of cell apoptosis was
induced (Fig. S4B,C).

Biology Open (2017) 6, 850-861 doi:10.1242/bio.024505

As p21 functions to mediate p53-dependent G1 arrest
(Brugarolas et al., 1995; Deng et al., 1995), we asked whether the
increased p21 expression upon Akt3 depeletion (Fig. 5E) is

Fig. 7. p53 activation is critical for Akt3-depletion inflicted G1-arrest and apoptosis. (A) R1-ESCs expressing pLKO.1 vector control (shCtl/R1) or shp53
(shp53/R1) were infected with lentiviral shCtl or shAkt3d on day 0, cells were grown for 3 days, then incubated with PI and RNase for 30 min and subjected
to cell cycle analysis. The percentages of cells in G1, S, and G2 phases are shown (data shown are mean±s.d., **P<0.01, n=2). (B) ESCs treated as described in
A were incubated with Annex and PI for 30 min and analyzed by flow cytometry. Percentages of live, early, and late apoptotic cells are shown (data shown
are mean±s.d., **P<0.01, n=2). (C) R1-ESCs expressing pLKO.1 vector control (shCtl/R1), shFas (shFas/R1), or shp21 (shp21/R1) were infected with lentiviral
shCtl or shAkt3d on day 0, grown for 3 days, then incubated with PI and RNase for 30 min and subjected to cell cycle analysis. The percentages of cells in G1,
S, and G2 phases are shown (data shown are mean±s.d., **P<0.01, n=2). (D) qRT-PCR Analysis of RNAs from R1-ESCs treated by shCtl, shAkt3d, or
shAkt3d plus shp53 for 72 h. All values were normalized to GAPDH and relative to ESCs treated with shCtl (data shown are mean±s.d., **P<0.01, n=2).
(E) qRT-PCR Analysis of RNAs from R1-ESCs treated by either shCtl, shAkt1, shAkt2, or shAkt3d for 72 h. All values were normalized to GAPDH and
relative to ESCs treated with shCtl (data shown are mean±s.d., *P<0.05, n=3).
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responsible for the ESC G1 arrest observed here. We generated
ESCs with ∼70% p21 knockdown (shp21/R1, Fig. S4D), and upon
Akt3-depletion using shAkt3d, we found that shp21/R1 cells
exhibited partial but significant rescue of G1 arrest induced, similar
to that of p53-knockdown (Fig. 7A,C). We also measured the p21
expression level with a double inhibition of Akt3 and p53. Akt3knockdown alone increased while a concomitant knockdown of p53
decreased the p21 expression (Fig. 7D), thus confirming the p53dependent increase of p21 expression upon Akt3 depletion in ESCs.
Knockdown of another p53 target, Fas, in ESCs (shFas/R1) also
showed partial rescue of the G1 arrest, although at a lesser degree
than the p21 knockdown (Fig. 7C). These data further confirmed
that the control of p53 pathway activity by Akt3 is a critical event for
ESC survival and proliferation, alongside the other mechanism(s) to
be elucidated.
Artificially activated Akt1 can sustain pluripotency of mouse
ESCs without LIF (Watanabe et al., 2006). Also, in human ESCs,
Akt prevents differentiation by mitigating Smad2/3-mediated
Activin-A signaling (Singh et al., 2012). We wondered if the
knockdown of Akt3 may cause ESC differentiation, therefore
leading to restricted cell proliferation observed in 2i/LIF medium
here. qRT-PCR analysis revealed that there was no significant
change to the expression of key pluripotency markers, including
Oct4, Sox2, Nanog, and Esrrb, upon Akt3 knockdown (Fig. 7E).
Therefore, depletion of Akt3 does not seem to promote the
differentiation of ESCs.
DISCUSSION

Akt regulates many downstream targets that affect cell proliferation
and survival. Both kinase-dependent and -independent activities of
Akt have been described for cell survival (Jirmanova et al., 2002;
Lianguzova et al., 2007; Vivanco et al., 2014). Delineation of the
Akt regulated signaling network is difficult because there are three
members in the Akt family that share structural similarities yet
render isoform-specific as well as overlapping functions (Gonzalez
and McGraw, 2009; Hanada et al., 2004; Manning and Cantley,
2007). We reported here for the first time a cell survival and
proliferation mechanism in ESCs that is Akt3-, but not Akt1- or
Akt2-, dependent. We also show that these effects of Akt3 are
dependent on its kinase activity. Akt3 is predominantly activated in
a number of cancers such as malignant melanoma and glioma, and
plays important roles in the survival of immortalized MEFs (Liu
et al., 2006; Mure et al., 2010; Stahl et al., 2004). In a recent study
we reported that Akt1 and Akt3 play non-redundant roles in
promoting primary MEF cell proliferation during somatic cell
reprogramming (Tang et al., 2014), indicating different mechanisms
governing cell growth by these two isoforms. One possible
mechanism that these Akt isoforms play different functions for
cell growth may be through differential cellular localization. It was
reported that in several human cancer cell lines, Akt1 localizes in
cytoplasm and Akt2 colocalizes with mitochondria, while Akt3
localizes in both nuclear membrane and nucleus (Santi and Lee,
2010). However, in clinical prostate cancer samples, Akt1 and -2
were reportedly localized both in cytoplasm and nucleus, whereas
Akt3 was observed in cytoplasm (Le Page et al., 2006). Therefore,
Akt isoform cellular localization may be cell type-specific. Exactly
how different Akt isoforms localize in ESCs is certainly of great
interest and worthy of further investigating.
p53 plays a central role in response to DNA damage repair
resulting in cell growth arrest and apoptosis (Lakin and Jackson,
1999; Meek, 2009; Sakaguchi et al., 1998; Smith and Seo, 2002).
Recent studies have also revealed a functional p53 in mouse ESCs.
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It was reported that in ESCs undergoing genotoxic damage, p53
protein suppresses the expression of certain pluripotency-related
genes yet activates differentiation-related genes, in addition to
activating the expression of Wnt-ligand genes (Lee et al., 2010; Li
et al., 2012). Additionally, p53 double knockout ESCs completely,
while ESCs with a single allele-mutated p53 ( p53+/R270H and
p53+/P275S) partially, resisted the apoptosis induced by the genotoxic
agent doxorubicin (de Vries et al., 2002). Our study for the first time
established a correlation between depletion of Akt3 and the
activation of p53 in ESCs at the post-transcription level.
We also demonstrated that blocking p53 expression partially
rescues the apoptotic and the G1 arrest effect of Akt3 inhibition, and
found that targeting p21 partially and significantly rescues the G1
arrest caused by Akt3 knockdown, in a similar fashion as p53
knockdown. Fas knockdown did not rescue apoptosis of ESCs
induced by Akt3 depletion (data not shown) but showed a slight
rescue to the G1 arrest, presumably due to the very low Fas
expression found in ESCs (Ginis et al., 2004), and also suggests
additional mechanisms parallel or downstream of p53 for the cell
survival. Recently, genetic analysis on highly malignant glioma
induced by Akt3 overexpression revealed a unique increase in gene
expression of the DNA repair pathway (Turner et al., 2015). Our
results complemented this finding and revealed that suppression of
p53 pathway activity is at least partially the underlying mechanism
for Akt3’s role in cell survival and proliferation.
We further found that these cell propagation protective functions
of Akt3 are associated with its kinase activity. It was previously
shown that in primordial germ cells, enhanced Akt1 activity inhibits
p53 phosphorylation at Ser20 (Kimura et al., 2008), a site necessary
for p53-induced cell cycle arrest and apoptosis at the G2/M phase
transition (Hirao et al., 2000; Shieh et al., 1999). Because Akt3
depletion does not impact the G2 hase in ESCs, our data indicate
that Akt3 may regulate p53 activity through a mechanism other than
phosphorylation of p53Ser20. Further study on the exact modification
on p53 protein by Akt3 is of particular interest, as p53 harbors
multiple phosphorylation sites for post-translational regulations
(Meek and Anderson, 2009).
It is obvious that mechanisms other than p53 activation are also
involved in Akt3 depletion-mediated apoptosis and cell cycle arrest.
One mechanism we could potentially exclude here is the GSK3specific inhibition by Akt3, as the 2i/LIF medium (Silva et al., 2008;
Ying et al., 2008) used in our study already contains GSK3
inhibitor, and western blotting also showed an increased rather than
decreased GSK3 phosphorylation in shAkt3 treated ESCs (Fig. 5C).
On the other hand, our study here indicates that there is a
compensatory increase of Akt1 activity to promote the survival of
ESCs suffering the depletion of Akt3. We also discovered that there
is a more severe effect on ESC survival by targeting both Akt1 and
Akt3 than by targeting Akt3 alone, although targeting Akt1 only
does not lead to cell apoptosis. Although our study here is restricted
to ESCs, other cell types could well exhibit similar mechanisms and
thus affect cell survival during embryo development. This correlates
with a previous mouse model showing that Akt1−/−/Akt3−/− mice
died at mid-gestation stage, whereas Akt3−/− mice were viable
(Tschopp et al., 2005; Yang et al., 2005). A previous study also
showed that a single Akt1 allele seems to be enough for the
embryonic and postnatal survival of Akt2−/−/Akt3−/− mice, albeit
with series of other postnatal defects (Dummler et al., 2006). Further
investigations are warranted to determine how Akt1 synergizes with
Akt3 to maintain cell survivability.
Overall our results illustrated an Akt3 mediated ESC survival and
G1/S-transition mechanism which involves the suppression of p53
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activity. The regulation of pluripotent stem cell self-renewal is of
great interest, as ESCs are promising tools for regenerative
medicine. At the same time, many cancer cells exhibit ESCspecific signatures, thus making ESCs a good model for the study of
the cancer cell signaling pathways (Kim and Orkin, 2011). The
convergence of Akt3 and p53 pathways for ESC survival and
proliferation as demonstrated here not only contributes to our
understanding of pluripotent stem cell self-renewal but also has
important implications in cancer research.
MATERIALS AND METHODS
Chemicals and expression constructs

Akt inhibitor MK2206 (MK), PI3K inhibitor LY294002, Erk inhibitor
PD0329501, and GSK3β inhibitor CHIR99021 were obtained from
SelleckChem (Houston, TX, USA). LIF, 100× EmbryoMax-2mecaptoethanol, and 200× NDiff Neuro-2 medium supplement were from
Millipore (Billerica, MA, USA). 50× B-27, 100× nonessential amino acids,
and 100× GlutaMax supplements, 100× penicillin/streptomycin, DMEM,
DMEM/F12, and neurobasal media were from Invitrogen (Grand Island,
NY, USA). pLKO.1-puro, pLKO.1-scramble shRNA control, Lenti- and
retro-viral packaging constructs pCMV-VSV-G, PUMVC, and psPAX2
(Stewart et al., 2003) were all obtained from Addgene (Cambridge, MA,
USA). pLKO.1-shRNA constructs against mouse Akt1, Akt2, p53, Fas, and
p21 were from Sigma (St. Louis, MO, USA). Constitutively active Akt3
(CA-Akt3), pLKO.1-shRNAs against Akt3 including shAkt3a and shAkt3b
were described previously (Tang et al., 2014), shAkt3d were similarly
constructed, with sequence information listed in Table S1. Kinase-dead
Akt3 (KD-Akt3) was generated from CA-Akt3 with the lysine 177 mutated
to methionine and cloned into pMCs vector from Cell Biolabs (San Diego,
CA, USA). The human embryonic kidney cell line 293T for viral packaging
was purchased from Invitrogen. All methods were carried out in accordance
with the protocols approved by the University of Connecticut Institutional
Biosafety Committee and Stem Cell Research Oversight Committee.
Cell culture and lentiviral preparation

R1 male ESC line was obtained from ATCC. CD1 mouse embryonic
fibroblasts (MEFs) were generated from E13.5 embryos as described
previously (Tang et al., 2011). R1 cells were grown on mitomycin C treated
CD1 MEF feeders and cultured in 2i/LIF medium with LIF (1×103 units/ml)
and 1× each 2-mecaptoethanol, GlutaMax, nonessential amino acids, and
penicillin/streptomycin as described (Silva et al., 2009; Ying et al., 2008).
For lenti- or retro-viral production, pLKO.1- or pMCs-constructs, together
with packaging plasmids psPAX2 or PUMVC, and pCMV-VSV-G were cotransfected into 293T cells using Fugene 6 (Promega, Madison, WI, USA).
Lenti- or retro-viruses were packaged and collected at 24 or 48 h after
transfection as described previously (Tang et al., 2014, 2012).
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Immunostaining

R1 cells were grown on 12 mm glass coverslips (Thermo Fisher Scientific) in
6-well plates seeded with CD1 MEFs as feeders, and treated by lentiviruses as
described in the Apoptosis and cell cycle assays section. Cells were fixed in 4%
paraformaldehyde with 1% sucrose in PBS for 15 min at room temperature.
The cell membranes were permeabilized with 0.5% Triton X-100 in PBS-T,
then incubated for 2 h at 37°C in 5% donkey or goat serum with mouse antiSSEA1 IgM (1:100, Abcam, Cambridge, MA, USA) or rabbit anti-p53 IgG
(1:100, Cell Signaling, Danvers, MA, USA), washed in PBS-T, and then
incubated with Alexa Fluor 594 conjugated donkey anti-rabbit or goat antimouse secondary antibodies (1:500, Invitrogen). After the washing, cells were
counterstained with DAPI and mounted under coverslips. Fluorescence images
were taken using a Nikon A1R Spectral confocal microscope and signal
densities were analyzed using the ImageJ software (Schneider et al., 2012).
Western blotting

R1 cells were grown in 6-well plates seeded with CD1 MEFs as feeders, and
treated by lentiviruses as described in the Apoptosis and cell cycle assays
section. Total cellular proteins were then extracted using RIPA buffer
(Thermo Fisher Scientific) with 1× proteinase and phosphatase inhibitors
(Thermo Fisher Scientific). Proteins were quantified with a BCAQuantification kit (Thermo Fisher Scientific), and subjected to 10% SDSPAGE gel electrophoresis using BioRad mini-gel system and subsequently
transferred to PVDF membranes.
The blotted membranes were then blocked with 5% non-fat dry milk in
TBS-T and incubated with primary antibodies at 4°C overnight. The
antibodies used were as follows: anti-GAPDH (1/2500, Abcam). Antibodies
against p53, Mdm2, pMdm2, and pGSK3β (1/1000 for all) were from Cell
Signaling. All Akt isoforms, phospho-Akt Ser473, and pan-Akt were detected
using Akt isoform antibody sampler kit from Cell Signaling. Membranes were
then washed and blotted with HRP conjugated goat anti-mouse or goat antirabbit secondary antibodies (1:5000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Chemiluminescence was detected either using Pierce ECL
Western-Blot Substrate (Thermo Fisher Scientific) and X-ray film exposure,
and quantified using the ImageJ software (Schneider et al., 2012), or detected
and quantified using BioRad Gel Doc XR System (Hercules, CA, USA).
Quantitative real time-reverse transcription polymerase chain
reaction (qRT-PCR)

Total RNA was extracted using the RNeasy Extraction kit (Qiagen), and
reverse transcribed using an iScript Advanced cDNA Synthesis Kit (BioRad). qRT-PCR was performed using iTaq Universal SYBR Green
Supermix (Bio-Rad) and the ABI 7500 Fast instrument. Sequence
information for the specific primers for qPCR were listed in Table S2.
The data were analyzed using the 7500 software version 2.0.2 provided with
the instrument. All values were normalized with GAPDH as the internal
control and relative mRNA expressions were quantified against control
lentivirus transduced R1 cells as the reference.

Apoptosis and cell cycle assays
Statistical analysis

Data were analyzed using one way ANOVA with Tukey’s multiple
comparisons, or the Student’s t-test. All experiments were repeated at
least two times (N≥2). Figures were presented as mean±s.d. *P<0.05 or
**P<0.01 was considered significantly different.
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